drugset / Trial / NCT04688242
Anal Dilatation Plus Probiotics Before Ileostomy Reduction for Low Anterior Resection Syndrome
Phase 2
Unknown
164 enrolled
Sixth Affiliated Hospital, Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is randomized, phase 2 trial in patients with rectal cancer undergoing sphincter-preserving proctectomy and temporary ileostomy, to explore the effects of anal dilatation plus probiotics administered per anus before ileostomy reduction in relieving postoperative bowel dysfunction known as low anterior resection syndrome (LARS).
Timeline
- Start
- 2021-02-20
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bacillus mesentericus TO-A | Unknown | — | Rectal |
| Subject | Rifaximin | Other / unclassified | — | Rectal |
| Subject | Streptococcus faecalisT-110 | Unknown | — | Rectal |
Indications
No indication recorded.